Search Results - "Groves, E. S."

A model for predicting the evolution of damage in viscoelastic particle-reinforced composites by Seidel, G.D., Allen, D.H., Helms, K.L.E., Groves, S.E.

“…A viscoelastic cohesive zone model is employed within the framework of a finite element code to analyze a two-phase viscoelastic particle-reinforced composite…”
Get full text

Mobility histories of 7th-9th century AD people buried at early medieval Bamburgh, Northumberland, England by Groves, S.E., Roberts, C.A., Lucy, S., Pearson, G., Gröcke, D.R., Nowell, G., Macpherson, C.G., Young, G.

“…ABSTRACT Early Medieval England is described historically as a time when people migrated from the Continent to English shores. This study tests the hypothesis…”
Get full text

Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies by Gould, B J, Borowitz, M J, Groves, E S, Carter, P W, Anthony, D, Weiner, L M, Frankel, A E

“…260F9 Monoclonal antibody-recombinant ricin A chain, an immunotoxin reactive with approximately 50% of breast carcinomas, was given by continuous iv infusion…”
Get more information

Stress analysis of a matrix-cracked viscoelastic laminate by Zocher, M.A., Allen, D.H., Groves, S.E.

“…Two distinctly different approaches to viscoelastic stress analysis are employed herein for the purpose of predicting the response of a matrix-cracked…”
Get full text

Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88 by DAIFUKU, R, HAENFTLING, K, YOUNG, J, GROVES, E. S, TURRELL, C, MEYERS, F. J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate by WEINER, L. M, O'DWYER, J, KITSON, J, COMIS, R. L, FRANKEL, A. E, BAUER, R. J, KONRAD, M. S, GROVES, E. S

“…Four women with metastatic breast cancer were treated with monoclonal antibody 260F9-recombinant ricin A chain, a ricin A chain immunoconjugate (IC) which…”
Get full text

An experimental and analytical treatment of matrix cracking in cross-ply laminates by GROVES, S. E, HARRIS, C. E, HIGHSMITH, A. L, ALLEN, D. H, NORVELL, R. G

“…The development of damage in cross-ply Hercules AS4/3502 graphite /epoxy laminates has been investigated. Specific endeavors were to identify the mechanisms…”
Get full text

A THREE-DIMENSIONAL FINITE ELEMENT FORMULATION FOR THERMOVISCOELASTIC ORTHOTROPIC MEDIA by ZOCHER, M. A., GROVES, S. E., ALLEN, D. H.

“…This paper is concerned with the development of a numerical algorithm for the solution of the uncoupled, quasistatic initial/boundary value problem involving…”
Get full text

Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study by Sanda, M G, Yang, J C, Topalian, S L, Groves, E S, Childs, A, Belfort, Jr, R, de Smet, M D, Schwartzentruber, D J, White, D E, Lotze, M T

“…Recombinant human macrophage colony-stimulating factor (M-CSF) has been shown to stimulate specifically macrophage lineage differentiation in vitro and to…”
Get more information

Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody by Perez, P, Titus, JA, Lotze, MT, Cuttitta, F, Longo, DL, Groves, ES, Rabin, H, Durda, PJ, Segal, DM

“…Heteroaggregates containing anti-T3 cross-linked to anti-target cell antibodies have been shown to cause human T cells to lyse target cells that express…”
Get full text

Adoptive immunotherapy of a syngeneic murine leukemia with a tumor- specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression by Matis, LA, Shu, S, Groves, ES, Zinn, S, Chou, T, Kruisbeek, AM, Rosenstein, M, Rosenberg, SA

“…The successful adoptive immunotherapy of the syngeneic Friend virus-induced murine leukemia FBL-3 was mediated by a proliferative MHC-restricted,…”
Get full text

Heat shock treatment releases Penicillium phosphoglycopeptide by Bonetti, Sandra J., Groves, Scott E., Black, Brent, Gander, John E.

“…Filtrates of heat (54°) treated day-5 Penicillium fellutanum cultures contained 70 mg of peptidophosphogalactomannan-II; an unheated control contained 30 mg…”
Get full text

Role of the H-2 complex in the induction of T cell tolerance to self minor histocompatibility antigens by GROVES, E. S, SINGER, A

“…The present study has utilized cytotoxic T lymphocyte (CTL) responses specific for minor histocompatibility (minor H) antigens as an experimental approach to…”
Get full text

The Effects of Through-thickness Compression on the Interlaminar Shear Response of Laminated Fiber Composites by DeTeresa, Steven J., Freeman, Dennis C., Groves, Scott E.

“…The effects of through-thickness compression on the interlaminar shear response of laminated fiber composites were studied. The combined stresses were…”
Get full text

Expression of MEL-14 antigen is not an absolute requirement for dissemination to lymph nodes after adoptive transfer of murine T lymphocyte clones by Bookman, MA, Groves, ES, Matis, LA

“…The inability of established antigen-specific murine T lymphocyte clones to recirculate well in vivo has been attributed to loss of the surface glycoprotein…”
Get full text

A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy by Zamkoff, K W, Hudson, J, Groves, E S, Childs, A, Konrad, M, Rudolph, A R

“…Twenty patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with…”
Get more information

Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2 by Shih, Y, Konrad, M W, Warren, M K, Childs, A, Paradise, C, Meyers, F J, Groves, E S

“…Polyethylene glycolated (pegylated) interleukin-2 (PEG IL-2) was administered as a weekly i.v. bolus to patients with metastatic cancer in a phase-I trial…”
Get more information

Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors by Pearson, J W, Fogler, W E, Volker, K, Riggs, C W, Gruys, E, Groves, E S, Wiltrout, R H, Longo, D L

“…We have demonstrated that, in the human ovarian carcinoma cell line (OVCAR-3), recombinant human interferon alpha (rHuIFN-alpha) potentiated in vitro…”
Get more information

Intraventricular immunotoxin therapy for leptomeningeal neoplasia by Laske, D W, Muraszko, K M, Oldfield, E H, DeVroom, H L, Sung, C, Dedrick, R L, Simon, T R, Colandrea, J, Copeland, C, Katz, D, Greenfield, L, Groves, E S, Houston, L L, Youle, R J

“…The goals of this clinical trial of intraventricular 454A12-rRA therapy were to identify dose-limiting toxicities, to evaluate the pharmacokinetics of…”
Get full text

Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL) by Negro-Vilar, A., Dziewanowska, Z., Groves, E. S., Stevens, V., Zhang, J. K., Prince, M., Martin, A., Sterry, W.

“…Abstract only 8026 Background: ONTAK®(Dd), a genetically engineered fusion protein combines the enzymatically active domain of diphtheria toxin with the…”
Get full text